Daniel L. Vasella, M.D.
Advisor at Time BioVentures
About
Daniel Vasella, M.D., is Chairman of the Board of Numab Therapeutics AG, having joined the board in 2019 and become Chairman in 2020. He previously served as Chairman of Novartis AG from 1999 to 2013 and as its CEO from 1996 to 2010, and earlier held CEO and senior development and marketing roles at Sandoz Pharma. He earned an M.D. from the University of Bern in 1980 and completed studies at Harvard Business School.
Invests in
Biotech
Investments
Board seats
American Express CompanyNumab Therapeutics AGPepsiCoSciClone Pharmaceuticals
As listed on the firm's website.
Colleagues at Time BioVentures
Bradford Cornell
Advisor at Time BioVentures
D.A. Wallach
General Partner at Time BioVentures
DA Wallach
General Partner at Time BioVentures
Jack Schoenfeld
Analyst at Time BioVentures
Jay Flatley
Advisor at Time BioVentures
Jim Allison, Ph.D.
Scientific Advisor at Time BioVentures
Leonard Schaeffer
Advisor at Time BioVentures
Pam Sharma, M.D., Ph.D.
Scientific Advisor at Time BioVentures